We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

In-A-Gambro DaVita

7 December 2004 By Robert Cyran

The Swedish medical group has agreed to sell its US dialysis business to DaVita at a 40% premium to recent deals. But getting this deal past regulators will be tough, given the industry s concentration and monopolistic practices.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)